Discover
PHVS
Pharvaris N.V.
36.37
2 x 26.64
2 x 46.40
bid
ask
-
1.63
4.29%
2 @ 07:30 PM
36.01 -0.36 (0.99%)
| Ytd | 31.06% | |
| 1y | 48.21% |
36.08
day range
38.20
20.96
52 week range
38.86
| Open | 38.20 | Prev Close | 38.00 | Low | 36.08 | High | 38.20 | Mkt Cap | 2.55B |
| Vol | 580.26K | Avg Vol | 724.28K | EPS | -3.00 | P/E | N/A | Forward P/E | -11.63 |
| Beta | -2.32 | Short Ratio | 3.36 | Inst. Own | 93.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 35.36 | 200-d Avg | 30.03 | 1yr Est | 58.38 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | -0.82 | N/A | N/A | N/A |
| 2026-08-12 | 2026-06 | -0.75 | -0.81 | -0.06 | -8.48% |
| 2026-05-12 | 2026-03 | -0.82 | -0.7 | 0.12 | 14.83% |
| 2026-04-02 | 2025-12 | -0.71 | -0.85 | -0.13 | -18.34% |
| 2025-11-12 | 2025-09 | -0.78 | -0.7 | 0.08 | 10.26% |
| 2025-08-12 | 2025-06 | -0.87 | -0.94 | -0.07 | -8.05% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-10 | Guggenheim | Upgrade | Buy | Buy |
| 2026-09-09 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-09-09 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-09-09 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-09-09 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-09-09 | Citizens | Upgrade | Market Outperform | Market Outperform |
Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-09-14 | ABELE STEFAN | Chief Operating Officer | 39.07K | Conversion of Exercise of derivative security |
| 2026-05-19 | BJORK ELISABETH | Director | 15.17K | Conversion of Exercise of derivative security |
| 2026-09-14 | GLASSMAN ROBERT R. | Director | 10.50K | Conversion of Exercise of derivative security |
| 2026-09-09 | LESAGE ANNE SIMONNE J PH.D. | Officer | 56.45K | Conversion of Exercise of derivative security |
| 2026-09-10 | LU PENG | President | 64.95K | Conversion of Exercise of derivative security |
| 2026-09-13 | MODIG BERNDT B.A.E | Chief Executive Officer | 1.08M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 6.57M | 238.78M | 10.04% |
| 2026-06-29 | General Atlantic, L.P. | 6.55M | 238.25M | 10.02% |
| 2026-06-29 | Foresite Capital Management IV, LLC | 4.78M | 173.80M | 7.31% |
| 2026-06-29 | venBio Partners LLC | 4.64M | 168.88M | 7.10% |
| 2026-06-29 | Viking Global Investors, L.P. | 3.65M | 132.87M | 5.59% |
| 2026-06-29 | Eqt Fund Management S.a R.l. | 3.42M | 124.55M | 5.24% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.37M | 49.94M | 2.10% |
| 2026-07-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 800.00K | 29.10M | 1.22% |
| 2026-06-29 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 644.59K | 23.44M | 0.99% |
| 2026-07-30 | Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 400.00K | 14.55M | 0.61% |
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 399.48K | 14.53M | 0.61% |
| 2026-07-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 333.34K | 12.12M | 0.51% |